[go: up one dir, main page]

AR098884A1 - NOTCH ACTIVATION CHANGES IN BREAST CANCER - Google Patents

NOTCH ACTIVATION CHANGES IN BREAST CANCER

Info

Publication number
AR098884A1
AR098884A1 ARP140104823A ARP140104823A AR098884A1 AR 098884 A1 AR098884 A1 AR 098884A1 AR P140104823 A ARP140104823 A AR P140104823A AR P140104823 A ARP140104823 A AR P140104823A AR 098884 A1 AR098884 A1 AR 098884A1
Authority
AR
Argentina
Prior art keywords
breast cancer
notch activation
activation changes
pest domain
changes
Prior art date
Application number
ARP140104823A
Other languages
Spanish (es)
Inventor
Anthony Ching Keith
A Olson Peter
Wang Kai
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR098884A1 publication Critical patent/AR098884A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Métodos para identificar y tratar pacientes con cáncer que tienen alteraciones de activación en el dominio PEST de Notch1, Notch2 o Notch3 (Proteínas transmembrana), con un inhibidor de la vía de señalización de Notch, tal como el inhibidor de g-secretasa PF-03084014, o una sal de aquel aceptable desde el punto de vista farmacéutico. Dominio PEST (Prolina P, Ácido Glutámico E, Serina S, Treonina T). Uso. Compuesto.Methods for identifying and treating cancer patients who have activation disorders in the PEST domain of Notch1, Notch2 or Notch3 (Transmembrane proteins), with a Notch signaling pathway inhibitor, such as the G-secretase inhibitor PF-03084014 , or a salt thereof pharmaceutically acceptable. PEST domain (Proline P, Glutamic Acid E, Serine S, Threonine T). Use. Compound.

ARP140104823A 2013-12-20 2014-12-19 NOTCH ACTIVATION CHANGES IN BREAST CANCER AR098884A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361919431P 2013-12-20 2013-12-20

Publications (1)

Publication Number Publication Date
AR098884A1 true AR098884A1 (en) 2016-06-22

Family

ID=58698503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104823A AR098884A1 (en) 2013-12-20 2014-12-19 NOTCH ACTIVATION CHANGES IN BREAST CANCER

Country Status (1)

Country Link
AR (1) AR098884A1 (en)

Similar Documents

Publication Publication Date Title
ECSP24031979A (en) THERAPEUTIC ACTIVE COMPOUNDS AND THEIR METHODS OF USE
CL2018000318A1 (en) Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)
CY1124729T1 (en) PHARMACEUTICAL FORMS OF ENZALUTHAMIDE
CY1124436T1 (en) BICYCLIC HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
CL2018001134A1 (en) Compositions and methods to inhibit arginase activity
BR112016009889A2 (en) gip-glp-1 double agonist compounds and methods
BR112015020466A2 (en) cdc7 inhibitors
MX383499B (en) THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
CL2018002727A1 (en) Medicine obtained by combining agonist fxr and arb
EA201790398A1 (en) METHODS OF TREATING LIVER DISEASES
MX393610B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12016500024A1 (en) Bromodomain inhibitor
EA201500934A1 (en) CARDIO AND NEPHROPROTECTIVE ANTI-DIABETIC THERAPY
MX2019010422A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kî´ related disorders.
MX2020010412A (en) Inhibitors of bruton's tyrosine kinase.
MX2017009449A (en) JAK INHIBITOR.
CL2015003690A1 (en) Use of pridopidine or a salt thereof to prepare a medication useful in the treatment of huntington's disease.
CL2016002971A1 (en) Combination.
MX2018003893A (en) DIAMINOPIRIMIDINE RECEPTOR MODULATORS P2X3 AND P2X2 / 3 FOR USE IN THE TOS TREATMENT.
MX2016015434A (en) Pharmaceutical combinations for treating cancer.
EA201690513A1 (en) COMBINATION OF MEK INHIBITOR AND ERK INHIBITOR FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
CL2017000050A1 (en) Combination Therapy for Cancer
UY35276A (en) New compounds that inhibit the activity of Lp-PLA2
ECSP16008797A (en) DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure